| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
hDP 0.9 nM (Ki) hCRTH2 6.6 nM (Ki) hEP1 15.678 μM (Ki) hEP2 989 nM (Ki) hEP3 319 nM (Ki) hEP4 1065 nM (Ki) hFP 553 nM (Ki) hIP >25 μM (Ki) hTP 6426 nM (Ki) Human Endogenous Metabolite
|
|---|---|
| ln Vivo |
Prostaglandin J2 (PGJ2; 33.4 μg/injection; unilateral injection into SNpc; once weekly; for 2 or 4 weeks) causes motor impairments and a progressive pathology resembling Parkinson's disease (PD) in rats[4]. It also activates microglia and astrocytes.
|
| Animal Protocol |
Animal/Disease Models: Sixteenweeks old Sprague Dawley male rats[4]
Doses: 33.4 μg/injection Route of Administration: Unilateral (right side) injections to the SNpc; once per week for 2 or 4 weeks Experimental Results: Induced progressive dopaminergic neuronal loss in the rat substantia nigra pars compacta (SNpc). Developed parkinsonian-like motor deficits in a progressive manner. |
| References |
|
| Additional Infomation |
Prostaglandin J2 belongs to the prostaglandin J class of compounds. Its structure is prostaglandin-5,9,13-trien-1-acid, with a carbonyl group substituted at position 11 and a hydroxyl group substituted at position 15 (5Z,13E,15S stereoisomers). It is a human metabolite, functionally related to prostaglandin D2, and is the conjugate acid of prostaglandin J2(1-). There are reports and data regarding the presence of prostaglandin J2 in humans.
|
| Molecular Formula |
C20H30O4
|
|---|---|
| Exact Mass |
334.214
|
| CAS # |
60203-57-8
|
| Related CAS # |
Prostaglandin J2-d4;2738376-80-0
|
| PubChem CID |
5280884
|
| Appearance |
Colorless to light yellow liquid
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
521.7±50.0 °C at 760 mmHg
|
| Flash Point |
283.4±26.6 °C
|
| Vapour Pressure |
0.0±3.1 mmHg at 25°C
|
| Index of Refraction |
1.555
|
| LogP |
3.34
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
24
|
| Complexity |
476
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
CCCCCC(C=CC1C(C=CC1=O)CC=CCCCC(=O)O)O
|
| InChi Key |
UQOQENZZLBSFKO-POPPZSFYSA-N
|
| InChi Code |
InChI=1S/C20H30O4/c1-2-3-6-10-17(21)13-14-18-16(12-15-19(18)22)9-7-4-5-8-11-20(23)24/h4,7,12-18,21H,2-3,5-6,8-11H2,1H3,(H,23,24)/b7-4-,14-13+/t16-,17-,18+/m0/s1
|
| Chemical Name |
(Z)-7-[(1S,5R)-5-[(E,3S)-3-hydroxyoct-1-enyl]-4-oxocyclopent-2-en-1-yl]hept-5-enoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
